Misplaced Pages

Golidocitinib

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.

Pharmaceutical compound
Golidocitinib
Clinical data
Trade names高瑞哲 (Gao Ruizhe)
Other namesAZD-4205, AZD4205, JAK1-IN-3
Legal status
Legal status
  • Rx in China
Identifiers
IUPAC name
  • (2R)-N-pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propanamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC25H31N9O2
Molar mass489.584 g·mol
3D model (JSmol)
SMILES
  • C(C(=O)NC1=CC=CC2=C1NC=C2C3=NC(=NC=C3)NC4=CN(N=C4OC)C)N5CCN(CC5)C
InChI
  • InChI=InChI=1S/C25H31N9O2/c1-16(34-12-10-32(2)11-13-34)23(35)28-20-7-5-6-17-18(14-27-22(17)20)19-8-9-26-25(29-19)30-21-15-33(3)31-24(21)36-4/h5-9,14-16,27H,10-13H2,1-4H3,(H,28,35)(H,26,29,30)/t16-/m1/s1
  • Key:CVCVOSPZEVINRM-MRXNPFEDSA-N

Golidocitinib is a pharmaceutical drug for the treatment of cancer. In June 2024, it was given conditional approval in China for the treatment of relapsed or refractory peripheral T-cell lymphoma.

Golidocitinib is classified as a Janus kinase inhibitor.

References

  1. Keam SJ (October 2024). "Golidocitinib: First Approval". Drugs. 84 (10): 1319–1324. doi:10.1007/s40265-024-02089-2. PMID 39298087.
  2. Song Y, Malpica L, Cai Q, Zhao W, Zhou K, Wu J, et al. (January 2024). "Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study". The Lancet. Oncology. 25 (1): 117–125. doi:10.1016/S1470-2045(23)00589-2. PMID 38092009.
  3. Jin J, Zhang L, Zou L, Li Z, Wu H, Zhou K, et al. (2024). "Maintenance Therapy of Golidocitinib, a JAK1 Selective Inhibitor, in Patients with Peripheral T Cell Lymphomas after First-Line Systemic Therapy: Updates of the Phase 2 Study (JACKPOT26)". Blood. 144: 6368. doi:10.1182/blood-2024-211891.
Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

Categories: